Print Page     Close Window     

SEC Filings

424B5
ONCOCYTE CORP filed this Form 424B5 on 02/07/2019
Entire Document
 

 

 

THE OFFERING

 

Common Stock offered by us               shares
     
Common stock to be outstanding immediately after this offering(1)                shares (or              shares if the underwriters exercise in full their option to purchase additional shares of common stock).
     
Option to purchase additional common stock   We have granted the underwriters an option to purchase up to             additional shares of common stock from us at the offering price. The underwriters can exercise this option at any time, but not more than once, within 30 days following the effective date of the purchase agreement between us and the underwriters.
     
Use of proceeds   We expect to receive net proceeds from this offering of approximately $              (or $             if the underwriters exercised their option to purchase additional shares of common stock in full), after deducting the underwriting discounts and commissions and the expenses of this offering payable by us. We currently intend to use the net proceeds from this offering to support DetermaVu™ commercialization efforts and additional clinical studies to support reimbursement and adoption, to initiate future product development, and for general corporate and working capital purposes. See “Use of Proceeds.”
     
Risk factors   Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page S-6 of this prospectus supplement and page 4 of the accompanying prospectus, as well as the documents and other information incorporated by reference in or included in this prospectus supplement, for a discussion of the risks you should carefully consider before investing in our common stock.
     
NYSE American symbol for our common stock   OCX

 

(1) The number of shares of our common stock to be outstanding immediately after this offering as shown above is based on 40,664,496 shares of our common stock outstanding as of September 30, 2018, and excludes:

 

  4,035,339 shares of our common stock issuable upon exercise of warrants outstanding as of September 30, 2018, with a weighted-average exercise price of $3.70 per share;

 

  4,540,000 shares of our common stock issuable upon exercise of options outstanding under our 2010 Stock Option Plan as of September 30, 2018, with a weighted-average exercise price of $2.94 per share, of which options to acquire 575,000 shares of our common stock have been exercised for net proceeds to us of $942,500 subsequent to September 30, 2018;

 

  230,000 shares of our common stock issuable upon exercise of options outstanding under our 2018 Equity Incentive Plan as of September 30, 2018, with a weighted-average exercise price of $2.40 per share; and

 

  4,770,000 shares of our common stock available for future grants under our 2018 Equity Incentive Plan as of September 30, 2018.

 

 

S-5

© Copyright BioTime, Inc.